Total
0
Shares
Imugene (ASX:IMU) - CEO, Leslie Chong
CEO, Leslie Chong
Source: Imugene
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Imugene (IMU) announced that cancer and research centre, City of Hope, has dosed the first patient in the phase one clinical trial of CHECKvacc
  • The study is recruiting patients with triple negative breast cancer (TNBC), testing the safety and efficacy of CHECKvacc against metastatic TNBC
  • Leading the trial is Yuan Yuan who says a new treatment will be “very much welcomed by both patients and the medical community”
  • Imugene is trading in the grey at 45 cents per share at 3:10 pm AEDT

Imugene (IMU) has announced that cancer and research centre, City of Hope, has dosed the first patient in the phase one clinical trial of CHECKvacc.

The study is recruiting patients with triple negative breast cancer (TNBC), testing the safety and efficacy of CHECKvacc against metastatic TNBC.

TNBC is an aggressive subtype of breast cancer which affects about 20 per cent of all breast cancer patients. The cancer rapidly develops resistance to chemotherapy, which means chemotherapy advances will mostly likely not improve prognosis.

CHECKvacc is a novel chimeric orthopoxvirus with robust anti-cancer activity
including TNBC xenografts.

Leading the trial is Yuan Yuan who said a new treatment will be “very much welcomed by both patients and the medical community.”

“Oncolytic viruses such as CHECKvacc certainly hold significant potential to improve clinical response and survival, and we’re looking forward to investigating this drug in patients,” Dr Yuan said.

Commenting on the trial is Chair of Sangiacomo Family Chair in Surgical Oncology at City
of Hope Professor Yuman Fong.

“It’s a proud moment to see CF33-hNIS-antiPDL1 (CHECKvacc) continue its progression and have this phase one trial underway with patients at City of Hope,” he said.

“While we are starting the oncolytic virus in triple negative breast cancer, given the significant unmet need, it holds promise across many cancer indications.”

On the market this afternoon, Imugene was in the grey and trading at 45 cents per share at 3:10 pm AEDT.

IMU by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) receives $524,000 R&D tax refund

Arovella Therapeutics (ALA) has received a refund from the Australian Taxation Office (ATO) of just over $524,000 for the financial year.